Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Small Molecules vs. Biologics: The Patent Playbook for Generics vs. Biosimilars Is Not One-Size-Fits-All
Most patent strategies fail for the same reason: they’re built for the wrong battlefield.
If you’re advising on generic entry or biosimilar competi…

Biopharma vendors don’t lose deals because they’re “too late.” They lose because they’re invisible—until it’s too late.
In EU markets, the tender cycle around loss of exclusivity (LoE) is brutal: once the patent clock runs out, procurement teams move f…

Pharma’s biggest “new drug” isn’t new at all. It’s an old molecule with a fresh label—and a new revenue stream.
For years, the industry has sold the public a simple story: innovation means discovery. But in practice, a growing share of pharmaceutical v…

Biopharma is entering a new kind of “cliff”—not just the patent cliff everyone talks about, but the operational cliff that shows up when exclusivity ends and price pressure hits overnight.
The market doesn’t wait for your next launch. It doesn’t care t…